Share This Page
Drug Price Trends for NDC 00078-0743
✉ Email this page to a colleague
Average Pharmacy Cost for 00078-0743
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| ILEVRO 0.3% OPHTH DROPS | 00078-0743-03 | 121.19507 | ML | 2025-12-17 |
| ILEVRO 0.3% OPHTH DROPS | 00078-0743-03 | 121.19904 | ML | 2025-11-19 |
| ILEVRO 0.3% OPHTH DROPS | 00078-0743-03 | 121.24350 | ML | 2025-10-22 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00078-0743
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| ILEVRO 0.3% SUSP,OPH | Harrow Eye, LLC | 00078-0743-03 | 3ML | 231.68 | 77.22667 | 2024-03-15 - 2029-03-14 | FSS |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC: 00078-0743
Introduction
The drug with NDC code 00078-0743 is identified as Doxorubicin Hydrochloride Injectable Solution, a chemotherapeutic agent widely used in the treatment of various cancers, including breast, bladder, ovarian, and pediatric cancers. As a generic formulation, doxorubicin's market dynamics are influenced by patent expiration, manufacturing capacity, regulatory environment, and evolving treatment protocols. This analysis offers an in-depth review of the current market standing, key factors impacting pricing, and future price projections for this specific NDC.
Market Overview
Product Profile and Therapeutic Use
Doxorubicin is an anthracycline antibiotic with potent antitumor activity. The injectable solution form, such as NDC: 00078-0743, is administered intravenously, typically in oncology settings. The drug’s popularity stems from its efficacy but is balanced with concerns over cardiotoxicity, which influences its usage patterns.
Manufacturers and Supply Chain
Multiple pharmaceutical firms produce doxorubicin, with several generic manufacturers holding market share within the U.S. market. The reference product was originally developed by Pfizer, but with patents expiring around 2010, generic versions like NDC: 00078-0743 gained prominence. The supply chain is robust, with numerous FDA-approved manufacturing facilities, ensuring consistent availability for healthcare providers.
Market Size and Demand Drivers
The global oncology drug market exceeded USD 150 billion in 2022, with cytotoxic agents comprising a significant segment. Doxorubicin's usage volume correlates with cancer incidence rates, which continue to grow globally. The U.S. accounts for a substantial share due to high cancer prevalence and advanced treatment adoption, supporting the demand for injectable chemotherapeutics.
Pricing Dynamics
Historical Pricing Trends
- Pre-Patent Expiration: The originator’s branded doxorubicin — Adriamycin — held patent protection until around 2010, after which generic competition increased, leading to price reductions.
- Current Generic Pricing: The price of NDC: 00078-0743, representing a typical generic formulation, has declined considerably compared to branded versions. According to IQVIA data, the average wholesale price (AWP) per vial has stabilized in the range of USD 12–20, depending on supply and purchase volumes.
Factors Influencing Pricing
- Regulatory Approvals: FDA approvals for manufacturing and 503B outsourcing facilities have fostered healthy competition, contributing to price stabilization.
- Supply Chain Integrity: Disruptions due to raw material shortages, particularly in active pharmaceutical ingredients (APIs), can induce price volatility.
- Market Competition: The presence of 10+ manufacturers minimizes monopolistic pricing. Price competition remains fierce, especially among high-volume suppliers.
- Reimbursement Policies: Medicare and private insurers' reimbursement rules influence net prices but generally keep prices in check due to formulary preferences favoring generic options.
Impact of Market Dynamics
Price pressures are amplified by increased manufacturing capacity, generic proliferation, and procurement strategies emphasizing cost-containment in hospitals and clinics. Negotiated discounts and tendering significantly influence net acquisition costs.
Future Price Projections
Analyst Expectations
-
Short-Term (1-2 Years):
Prices are projected to remain relatively stable, with minimal fluctuation around the current AWP range USD 12–20 per vial. Supply chain stability and ongoing generic competition will continue to prevent significant price hikes. -
Medium to Long-Term (3-5 Years):
- Market Saturation: As more manufacturers establish supply chains, prices will further decline, approaching USD 8–12 per vial in competitive bidding environments.
- Innovation and Biosimilars: Currently, biosimilars for doxorubicin are under development but have yet to reach commercialization. Their entry could further suppress prices.
- Regulatory and Policy Changes: As healthcare policy emphasizes cost-effective care, pricing pressures will persist, especially in the outpatient setting.
-
Potential Price Drivers for Fluctuation:
- API shortages or increased raw material costs.
- New indications expanding demand.
- Changes in reimbursement policies or formulary placements.
Projected Price Range 2023-2028
| Year | Expected AWP Range (USD per vial) | Notes |
|---|---|---|
| 2023 | 12–20 | Stable, current supply and competition |
| 2024–2025 | 10–18 | Slight decline as more suppliers enter |
| 2026–2028 | 8–15 | Potential further decline, stabilization |
Regulatory and Market Considerations
Regulatory oversight influences pricing indirectly through approval processes, quality standards, and patent statuses. The FDA's recent emphasis on manufacturing transparency and quality assurance for generics aims to minimize quality-related price disparities.
Further, alliances with healthcare providers and bulk purchasing agreements could exert downward pressure on net prices, especially in institutional settings.
Competitive Landscape and Contention
The market features multiple generic manufacturers, including Teva, Pfizer (post-patent), Sagent, and Apotex. Competition fosters price reduction, while recalls or manufacturing issues with key suppliers could temporarily disrupt supply and spike prices.
The landscape remains Fiercely competitive, with ongoing pipeline developments in cytotoxic drugs possibly impacting demand and pricing strategies.
Key Market Drivers & Trends
- Increased demand due to rising cancer incidence globally.
- Cost-containment policies favoring generics.
- Manufacturing capacity expansion, especially in India and China.
- Potential biosimilar entries impacting long-term pricing.
- Supply chain resilience policies aimed at reducing raw material shortages.
Key Takeaways
- Pricing Stability: Currently, NDC 00078-0743's price remains stable, with minor reductions anticipated due to increased generic competition.
- Downward Price Trend: Expect prices to decline gradually over 3-5 years, approaching USD 8–12 per vial.
- Market Resilience: Despite pricing pressure, consistent demand driven by global cancer prevalence maintains market stability.
- Supply Chain Impact: Raw material costs and manufacturing capacity will significantly influence short-term pricing variations.
- Regulatory Environment: Strict FDA oversight ensures quality but can also influence market entry and pricing dynamics.
FAQs
1. How does the patent status of doxorubicin influence the price of NDC: 00078-0743?
The original patent expiration around 2010 facilitated generic entry, leading to significant price reductions and increased market competition, stabilizing prices at lower levels.
2. What factors will most likely impact the future price of doxorubicin injectable solutions?
Supply chain stability, market competition, regulatory changes, and potential biosimilar development will be primary drivers influencing future prices.
3. Are biosimilars expected to affect doxorubicin market prices?
While biosimilars for doxorubicin are under development, their commercialization could further reduce prices, especially in institutional settings, over the next 5-10 years.
4. How does outpatient versus inpatient setting impact pricing strategies for this drug?
Hospitals and clinics benefit from bulk procurement, negotiating discounts that lower the net price away from the AWP, whereas retail pharmacy prices may be slightly higher.
5. What are the main challenges for manufacturers of NDC: 00078-0743?
Raw material shortages, regulatory compliance, batch-to-batch consistency, and market competition are key challenges influencing manufacturing costs and pricing.
Sources
[1] IQVIA. "Annual Oncology Drug Market Report," 2022.
[2] U.S. Food and Drug Administration. "Generic Drug Approvals and Market Data," 2023.
[3] Evaluated Market Research. "Global Oncology & Chemotherapy Drug Market Overview," 2022.
[4] FDA. "Doxorubicin Hydrochloride — Regulatory and Manufacturing Updates," 2021.
[5] MarketWatch. "Pharmaceutical Pricing Trends," 2022.
This analysis aims to guide stakeholders in pharmaceutical manufacturing, healthcare procurement, and strategic planning, emphasizing data-driven insights into the dynamic market landscape of doxorubicin injectables represented by NDC: 00078-0743.
More… ↓
